EICHORPublic-registry site landscape for NCT05907122, “A Study to Evaluate Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected Melanoma”, a Melanoma study sponsored by Amgen. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT05907122 (registry record) |
| Study title | A Study to Evaluate Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected Melanoma |
| Official title | A Randomized, Double-blind Study Evaluating Pharmacokinetic Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Resected Stage III or Stage IV Melanoma Subjects in the Adjuvant Setting |
| Sponsor | Amgen |
| Condition(s) | Melanoma |
| Phase | PHASE3 |
| Listed sites | 76 |
| Site countries | United States, Argentina, Bosnia and Herzegovina, Brazil, Chile, Croatia, Georgia, Italy, Japan, Lithuania, Malaysia, Mexico |
Patient-friendly overview of this study: eichor.com/study/NCT05907122.
Eichor generates a preliminary site-risk snapshot for NCT05907122 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
Other Melanoma trials
More from Amgen
← Eichor home · All tracked trials · Melanoma studies · Weekly briefs
